Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces it will be hosting a Capital Markets Day for all investors on Wednesday 12 June 2019.
A welcome and introduction will be given by Richard Morgan, Chairman of Polarean Imaging. The morning will also feature presentations by:
· Bastiaan Driehuys, PhD, Founder and Chief Technology Officer
· Richard Hullihen, CEO of Polarean Imaging
· Jason Woods, PhD, Director at the Center for Pulmonary Imaging Research at Cincinnati Children's Medical Center
· Sudarshan Rajagopal, MD, PhD, Duke University (pre-recorded presentation)
The event will take place at the London Stock Exchange, 10 Paternoster Square, London EC4M 7LS at 9.30am, when a light breakfast will be served, for a 10.00am start. Please be aware that all visitors will require photo identification and will be subject to a brief security check on arrival to the building so allow sufficient time for this.
The presentations will be followed by tea and coffee, and a chance to network with all members of the Company's management team in attendance.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site.
The company’s drug-device...